ZPY-CpG-Ch, a broad coverage vaccine against Streptococcus pneumoniae

Area of Science:

• Vaccinology
• Microbiology
• Immunology

Background:

• Existing pneumococcal vaccines reduce invasive pneumococcal disease but face challenges from drug-resistant strains and serotype replacement.
• There is an urgent need for next-generation vaccines offering broader, serotype-independent protection.

Purpose of the Study:

• To discover and preclinically evaluate ZPY-CpG-Ch, a novel broad-coverage protein-based pneumococcal vaccine formulation.
• To assess its protective efficacy and immunogenicity compared to existing vaccines.

Main Methods:

• Preclinical evaluation in adult and neonatal murine models.
• Testing of various adjuvants, protein combinations, and doses.
• Challenge experiments with vaccine- and non-vaccine-covered serotypes, using Prevnar-13 as a benchmark.

Main Results:

• ZPY-CpG-Ch demonstrated greater cross-serotype protection than Prevnar-13.
• Enhanced efficacy was primarily attributed to T helper 17 (T_H17)-biased immune responses.
• Prevnar-13 showed robust efficacy, serving as a reliable benchmark.

Conclusions:

• ZPY-CpG-Ch shows significant promise as a next-generation pneumococcal vaccine.
• Genome-guided, protein-based vaccines can overcome limitations of current serotype-based approaches.
• This represents a meaningful step toward a universal pneumococcal vaccine.